Clinical Trial Detail

NCT ID NCT02506153
Title High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Interferon alpha-2b

Pembrolizumab

Age Groups: adult

No variant requirements are available.